Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05140941Phase 4Active Not Recruiting

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

Role: lead

NCT04382404Phase 1Completed

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Role: lead

NCT03282799Phase 2Completed

Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

Role: lead

All 3 trials loaded